All News

The designation is for all patients with low-grade serous ovarian cancer, regardless of their KRAS status and after 1 or more prior lines of therapy.

Continuous glucose monitoring (CGM) is a valuable tool in managing diabetes, offering real-time data on glucose levels throughout the day.

Tocilizumab-aazg (Tyenne; Fresenius Kabi) is the first approved biosimilar to tocilizumab (Actemra; Genentech) as both intravenous and subcutaneous.

Diabetes is a known risk factor for cognitive decline and small vessel disease.

Vitamin D preserved insulin-producing cells and cell function, which can reduce complications in young patients.

They also compared the approach of the European Medicines Agency and the FDA in drug approvals.

The device conducts blood biomarker tests that accurately diagnose amyloid pathology and can assist in diagnosing Alzheimer disease in patients with cognitive impairment.

The at-home test offers the availability to assess for all viruses using one tool.

Findings emphasize the importance of further research on effective and safe alternative treatments for MDD in children and adolescents, specifically in patients who are refractory to nonpharmacologic treatment and/or standard of care antidepressants

Findings showed that pharmacists frequently communicated with patients to implement complex plans.

A phase 1 study previously demonstrated that MW032 and denosumab were bioequivalent in pharmacokinetics, pharmacodynamics, safety, and immunogenicity.

Artificial intelligence (AI) recommendations resulted in fewer recurrent strokes, heart attacks, or vascular death within 3 months of a previous ischemic stroke.

This episode highlights how celebrity endorsements and local influencers can be leveraged to address vaccine hesitancy by shaping attitudes, but also must account for factors like audience trust and the potential for both benefits and limitations.

The continuous glucose monitoring system will be available for purchase online and without a prescription starting in summer 2024.

The CORe initiative is aimed at promoting inclusivity, reducing startup time for clinical trials, and facilitating data sharing to address recruitment and retention challenges in cancer research at community oncology sites.

Denosumab-bbdz (Wyost; Sandoz) and denosumab-bbdz (Jubbonti; Sandoz) are approved as interchangeable for all indications of denosumab (Xgeva and Prolia; Amgen).

This designation makes CBL-514 the first drug to receive both Orphan Drug Designation and Fast Track Designation for the treatment of Dercum disease.

Investigators also found that those with community-acquired, radiology-confirmed pneumonia with lower respiratory tract infections had worse outcomes.

The next-generation SRI was previously granted an Orphan Drug Designation in November 2023 and its safety and efficacy are currently being evaluated in clinical trials.

The novel therapy is also being evaluated for the treatment of solid tumors in pancreatic and non-small cell lung cancers.

Children with normal weight had different community relationships compared to children with overweight or obesity.

There have been ongoing concerns about the long-term effects of prenatal exposure on neurodevelopment.

In the study, investigators found superior kidney outcomes with injectable semaglutide (Ozempic) for individuals with type 2 diabetes and chronic kidney disease.

Laws can help eliminate common barriers to transparency but are not the only way to achieve health care transparency.

Juvéderm Voluma XC (AbbVie) is the first and only hyaluronic acid dermal filler to receive FDA approval for this indication with results lasting up to 13 months.

Study findings could provide scientists more knowledge on why some populations face a higher risk of lung cancer compared to others.

According to the researchers, making changes to the daylight saving time system to accommodate heart health is unnecessary.

The regimen, which was used as second-line treatment in patients with drug-resistant TB, had a similar microbiological response to those with drug-sensitive TB taking first-line regimens.

In some instances, metabolites can predict risk in patients who still have normal glucose biomarkers.

AAO-HNSF guideline development group included 17 panel members, including experts from otolaryngology and allergy, those who have knowledge in clinical practice guideline development, and patient representatives.